Andere talen Kintara Therapeutics, Inc.

Aandelen

KTRA

US49720K2006

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,1488 ^USD	-5,82%		+22,57%	-12,26%

03/04	Sectorupdate: Aandelen gezondheidszorg eind van de middag zachter	MT
03/04	Sectorupdate: Gezondheidszorg	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	26/04
Kintara Therapeutics : TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Form 8-K	25/04
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA	10/04
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA	05/04
Sector Update: Health Care Stocks Softer Late Afternoon	03/04
Sector Update: Health Care	03/04
Top Midday Gainers	03/04
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA	03/04
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders	03/04
TuHURA Biosciences, Inc. entered into a definitive agreement to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.	03/04
TuHURA Biosciences, Inc. agreed to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.	03/04
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab	27/03
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab	27/03
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Kintara Therapeutics Continues to Evaluate Strategic Options	15/02
Kintara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update	14/02
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer	12/02
Kintara Therapeutics, Inc. Announces Initiation of Rem-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer	12/02
Wall Street Set for Cautious Opening in Final Trading Day of a Bullish 2023	29/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kintara Therapeutics, Inc.

Aandelen

KTRA

US49720K2006

Andere talen

Filters